Apixaban 'better than aspirin' in atrial fibrillation

Researchers have stopped a Phase III trial of a new anticoagulant in patients with atrial fibrillation after a predefined interim analysis revealed overwhelming evidence of efficacy.

During atrial fibrillation, blood tends to pool in the atria – increasing the risk of thrombosis and stroke
During atrial fibrillation, blood tends to pool in the atria – increasing the risk of thrombosis and stroke

Compared with aspirin, apixaban more than halved the risk of stroke in patients with atrial fibrillation enrolled in the AVERROES trial, researchers reported at the European Society of Cardiology congress in Stockholm on 31 August. Like rivaroxaban, apixaban is a direct inhibitor of Factor Xa.

"The results of AVERROES are truly impressive," said lead investigator Stuart Connolly, a professor of medicine at McMaster University in Canada. "It appears that apixaban will be an excellent treatment for the many patients with atrial fibrillation who are unsuitable for warfarin. These findings will reduce the burden of stroke in society."

The randomised, double-blind trial recruited 5,600 patients who were unsuitable for treatment with vitamin K antagonists such as warfarin. Participants received apixaban at a dose of 5mg twice daily or aspirin at a dose of 81–324mg once daily.

A prespecified analysis of interim data showed that the relative risk of stroke or systemic embolism (the combined primary end point) was 54% lower in the apixaban-treated patients than in the aspirin-treated patients (p<0.001). The relative risk reduction for stroke alone was 52% (p<0.001).

Importantly, rates of major bleeding events were comparable in the two groups.

Apixaban has already shown promising results in patients with deep vein thrombosis, and for thromboprophylaxis following orthopaedic surgery and acute coronary syndromes.

The ongoing ARISTOTLE trial is comparing apixaban with warfarin in patients with atrial fibrillation who are suitable for treatment with the vitamin K antagonist.

Bristol-Myers Squibb and Pfizer are co-developing the drug.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases